IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease

Current Opinion in Investigational Drugs

Volumn 11, Issue 5, 2010, Pages 527-534

  Mitchell, Jesse ^a   Dimov, Vesselin ^b   Townley, Robert G ^b  

^a CREIGHTON UNIVERSITY   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergy; Asthma; Bronchial hyper responsiveness; IL 13; IL 13R 1; IL 13R 2; IL 4R

Indexed keywords

ACETYLCHOLINESTERASE; AEROVANT; ALTRAKINCEPT; AMG 317; ANTIALLERGIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHEMOKINE RECEPTOR CCR5; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; FLUTICASONE; GM 1 E 7; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 13 E13K; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4 INHIBITOR; INTERLEUKIN 5 INHIBITOR; LEBRIKIZUMAB; MONOCLONAL ANTIBODY; PITRAKINRA; PLACEBO; QAX 576; RECOMBINANT PROTEIN; RECOMBINANT THROMBOCYTE ACTIVATING FACTOR; SALBUTAMOL; SMALL INTERFERING RNA; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ASTHMA; BRONCHUS HYPERREACTIVITY; CELL INFILTRATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EOSINOPHIL; ETIOLOGY; HUMAN; IMMUNOGLOBULIN PRODUCTION; LUNG FIBROSIS; MUCUS SECRETION; NONHUMAN; REPEATED DRUG DOSE; RESPIRATORY TRACT INFLAMMATION; REVIEW; RNA INTERFERENCE; TH2 CELL;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; RECEPTORS, INTERLEUKIN-13; TH2 CELLS; TREATMENT OUTCOME;

EID: 77952126162     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Wills-Karp M: Interleukin-13 in asthma pathogenesis. Immunol Rev (2004) 202:175-190. •• Highlights the importance of IL-13 in asthma, airway inflammation and BHR. (Pubitemid 39576912)
2. Schroder NWJ, Maurer M: The role of innate immunity in asthma: Leads and lessons from mouse models. Allergy (2007) 62(6):579-590.
3. Beasley R, Crane J, Lai CK, Pearce N: Prevalence and etiology of asthma. J Allergy Clin Immunol (2000) 105 (2 Pt 2) : S466-S472.
4. Barnes P: Against the Dutch hypothesis: Asthma and chronic obstructive pulmonary disease are distinct diseases. Am J Respir Crit Care Med (2006) 174(3):240-243.
5. Sokol CL, Barton GM, Farr AG, Medzhitov R: A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol (2008) 9(3):310-318.
6. Wynn TA: Basophils trump dendritic cells as APCs for Th2 response. Nat Immunol (2009) 10(7):679-681. • Provided strong evidence of the role of basophils in initiation of the allergen-induced Th2 response.
7. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z, Elias JA, Sheppard D, Erle DJ: Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med (2002) 8(8):885-889. •• Demonstrated that IL-13 is necessary and sufficient to induce BHR and excess mucus production in the absence of inflammatory cells (ie, eosinophils and T-lymphocytes).
8. Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener-Kronish JP, Locksley RM: Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med (1996) 183(1):109-117.
9. Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R: Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am J Respir Cell Mol Biol (1995) 12(3):254-259.
10. Gavett SH, Chen X, Finkelman F, Wills-Karp M: Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J Respir Cell Mol Biol (1994) 10(6):587-593.
11. Lukacs NW, Strieter RM, Chensue SW, Kunkel SL: Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma. Am J Respir Cell Mol Biol (1994) 10(5):526-532.
12. Karras JG, Crosby JR, Guha M, Tung D, Miller DA, Gaarde WA, Geary RS, Monia BP, Gregory SA: Anti-inflammatory activity of inhaled IL-4 receptor-α antisense oligonucleotide in mice. Am J Respir Cell Mol Biol (2007) 36(3):276-285.
13. Ma B, Liu W, Homer RJ, Lee PJ, Coyle AJ, Lora JM, Lee CG, Elias JA: Role of CCR5 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol (2006) 176(8):4968-4978. •• Studies in IL-13 transgenic mice demonstrated the importance of IL-13 in emphysema and supported the hypothesis of a common mechanism of asthma and emphysema, as well as the downstream effects of IL-13 being mediated by CCR5.
14. Townley RG, Gendapodi PR, Qutna N, Evans J, Romero FA, Abel P: Effect of interleukin 13 on bronchial hyperresponsiveness and the bronchoprotective effect of β-adrenergic bronchodilators and corticosteroids. Ann Allergy Asthma Immunol (2009) 102(3):190-197. •• Describes the association between IL-13 and corticosteroid resistance, as well as a marked reduction in bronchodilating effect of β-adrenergic agonists.
15. Wills-Karp M: Interleukin-13: Central mediator of allergic asthma. Science (1998) 282(5397):2258-2261. •• Established IL-13 as the central mediator of allergic asthma.
16. Townley RG: IL-13 and the β-adrenergic blockade theory of asthma revisited 40 years later. Ann Allergy Asthma Immunol (2007) 99(3):215-224.
17. Therien AG, Bernier V, Weicker S, Tawa P, Falgueyret JP, Mathieu MC, Honsberger J, Pomerleau V, Robichaud A, Stocco R, Dufresne L et al: Adenovirus IL-13-induced airway disease in mice: A corticosteroid-resistant model of severe asthma. Am J Respir Cell Mol Biol (2008) 39(1):26-35.
18. Hershey GK: IL-13 receptors and signaling pathways: An evolving web. J Allergy Clin Immunol (2003) 111(4):677-690. •• An excellent review of IL-13 receptors that provides the background knowledge for preclinical and clinical studies of IL-13 and IL-13 receptor antagonists.
19. Holgate ST, Polosa R: Treatment strategies for allergy and asthma. Nat Rev Immunol (2008) 8(3):218-230.
20. Ramalingam TR, Pesce JT, Sheikh F, Cheever AW, Mentink-Kane MM, Wilson MS, Stevens S, Valenzuela DM, Murphy AJ, Yancopoulos GD, Urban JF Jr et al: Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor α1 chain. Nat Immunol (2008) 9(1):25-33.
21. Munitz A, Mingler M, Finkelman FD, Rothenberg ME: Distinct roles for IL-13 and IL-4 via IL-13 receptor α1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci USA (2008) 105(20):7240-7245.
22. O'Toole M, Legault H, Ramsey R, Wynn TA, Kasaian MT: A novel and sensitive ELISA reveals that the soluble form of IL-13Rα2 is not expressed in plasma of healthy or asthmatic subjects. Clin Exp Allergy (2008) 38(4):594-601.
23. Townley RG, Horiba M: Airway hyperresponsiveness: A story of mice and men and cytokines. Clin Rev Allergy Immunol (2003) 24(1):85-110.
24. Madhankumar AB, Mintz A, Debinski W: Alanine-scanning mutagenesis of α-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. J Biol Chem (2002) 277(45):43194-43205.
25. Daines MO, Chen W, Tabata Y, Walker BA, Gibson AM, Masino JA, Warrier MR, Daines CL, Wenzel SE, Hershey GK: Allergen-dependent solubilization of IL-13 receptor α2 reveals a novel mechanism to regulate allergy. J Allergy Clin Immunol (2007) 119(2):375-383. • Describes a situation in which allergens (eg, HDMs and certain molds) are able to decrease the efficacy of IL-13Rα2 and thereby increase the deleterious effect of IL-13. This study also demonstrated that the level of IL-13Rα2 in the BAL was markedly decreased in patients with asthma compared with healthy individuals.
26. Charo IF, Ransohoff RM: The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 354(6):610-621.
27. Grunig, G, Warnock, M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB: Requirement for IL-13 independently of IL-4 in experimental asthma. Science (1998) 282(5397):2261-2263. • Helped first establish IL-13 as an important cytokine in asthma pathogenesis.
28. Mitchell JH, Gendapodi PR, Carroll B, Takeshita S, McChesney A, Bastola N, Townley RG: Anti-CCR5 inhibits IL-13 induced bronchial hyperresponsiveness (BHR). J Allergy Clin Immunol (2009) 123 (2 Suppl) : S147.
29. Suzaki Y, Hamada K, Nomi T, Ito T, Sho M, Kai Y, Nakajima Y, Kimura H: A small-molecule compound targeting CCR5 and CXCR3 prevents airway hyperresponsiveness and inflammation. Eur Respir J (2008) 31(4):783-789.
30. Leckie MJ, ten Brincke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur M, Cowley H, Chung KF, Djukanovic RJ, Hansel TT et al: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet (2000) 356(9248):2144-2148.
31. Holgate ST: Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Allergol Int (2004) 53(2):47-54.
32. Henig NR, Aitken ML, Liu MC, Yu AS, Henderson WR Jr: Effect of recombinant human platelet-activating factoracetylhydrolase on allergen-induced asthmatic responses. Am J Respir Crit Care Med (2000) 162(2):523-527.
33. Freitag A, Watson RM, Matsos G, Eastwood C, O'Byrne PM: Effect of a platelet-activating factor antagonist, WEB 2086, on allergen induced asthmatic responses. Thorax (1993) 48(6):594-598.
34. Kuitert LM, Angus RM, Barnes NC, Barnes PJ, Bone MF, Chung KF, Fairfax AJ, Higenbotham TW, O'Connor BJ, Piotrowska B: Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med (1995) 151(5):1331-1335.
35. Kuitert LM, Hui KP, Uthayarkumar S, Burke W, Newland AC, Uden S, Barnes NC: Effect of the platelet-activating factor antagonist UK-74, 505 on the early and late response to allergen. Am Rev Respir Dis (1993) 147(1):82-86.
36. Casale TB, Stokes JR: Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol (2008) 121(2):288-296.
37. Corry DB, Kheradmand F: Biology and therapeutic potential of the interleukin-4/interleukin-13 signaling pathway in asthma. Am J Respir Med (2002) 1(3):185-193.
38. Blease K: Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling. Curr Opin Investig Drugs (2008) 9(11):1180-1184.
39. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 103(6):779-788.
40. Borowski A, Kuepper M, Horn U, Knupfer U, Zissel G, Hohne K, Luttmann W, Krause S, Virchow JC Jr, Friedrich K: Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces pro-fibrotic gene expression in lung fibroblasts. Clin Exp Allergy (2008) 38(4):619-628.
41. Bree A, Schlerman FJ, Wadanoli M, Tchistiakova L, Marquette K, Tan XY, Jacobson BA, Widom A, Cook TA, Wood N, Vunnum S et al: IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol (2007) 119(5):1251-1257.
42. MedImmune LLC: MedImmune advances asthma program with start of a phase 2 trial in Europe and Australia and first U. S.-based clinical trial for antibody targeting IL-13. Press Release (2008) : April 15. pressroom.medimmune.com/press- releases/2008/04/15/medimmune-advances-asthma-programwith-start-of-a-phase-2- trial-in-europe-and-australia-and-first-u-sbased-clinical-trial-for-antibody- targeting-il-13
43. Kasaian MT, Miller DK: IL-13 as a therapeutic target for respiratory disease. Biochem Pharmacol (2008) 76(2):147-155.
44. Kasaian MT, Tan XY, Jin M, Fitz L, Marquette K, Wood N, Cook TA, Lee J, Widom A, Agostinelli R, Bree A et al: Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther (2008) 325(3):882-892.
45. Corren J, Busse W, Meltzer E, Mansfeld L, Bensch G, Chon Y, Dunn M, Weng H, Lin S: Efficacy and safety of AMG 317, an IL-4Rα antagonist, in atopic asthmatic subjects: A randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol (2009) 123(3):732).
46. ™ in asthma patients. Press Release (2007) : January 03. www.aerovance.com/news/press-releases/Press-Releases/ Aerovance-Announces-Positive-Top-Line-Results-from-Phase-2a-Trial-of-Inhaled- AEROVANT-in-Asthma-Patients-88/
47. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M: Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet (2007) 370(9596):1422-1431. • Demonstrated a clinically significant protection of IL-4 variant in the late phase of an allergen challenge in patients with asthma.
48. ™ for the treatment of uncontrolled asthma. Press Release (2009) : March 02. www.aerovance.com/news/pressreleases/Press-Releases/ Aerovance-Initiates-Phase-IIb-Clinical-Trialwith-AEROVANT-for-the-Treatment-of- Uncontrolled-Asthma-80/
49. Krause S, Behrends J, Borowski A, Lohrmann J, Lang S, Myrtek D, Lorenzen T, Virchow JC, Luttmann W, Friedrich K: Blockade of interleukin-13-mediated cell activation by a novel inhibitory antibody to human IL-13 receptor α1. Mol Immunol (2006) 43(11):1799-1807.
50. Gendapodi PP, Kioi M, Puri RK, Abel P, Townley RG: Effect of IL-13 and IL-13 mutant (IL-13E13K) on airway hyperresponsiveness (AHR) and airway smooth muscle (ASM) in mice. J Allergy Clin Immunol (2007) 119 (Suppl 1) : S136-S137.
51. Walker W, Healey GD, Hopkin JM: RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-mediated events in lung epithelial cells. Immunology (2009) 127(2):256-266.
52. Darcan-Nicolaisen Y, Meinicke H, Fels G, Hegend O, Haberland A, Kuhl A, Loddenkemper C, Witzenrath M, Kube S, Henke W, Hamelmann E: Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice. J Immunol (2009) 182(12):7501-7508.
53. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV: T-helper type 2-driven inflammation defnes major subphenotypes of asthma. Am J Respir Crit Care Med (2009) 180(5):388-395.